RECRUITING

An Observational Extension Study for Adult Patients Treated in Study R5459-RT-1944 Who Receive a Kidney Transplant

Talk to us

Conditions

Chronic Kidney Disease (CKD)Kidney Transplant

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The main purpose of this study is to continue to see how vonsetamig works in the body and to monitor the outcomes after kidney transplant for participants previously treated in the R5459-RT-1944 study (NCT05092347). No study drug will be given during this study.

Official Title

A Noninterventional Extension Study for Patients Treated in Study R5459-RT-1944 With Vonsetamig (BCMA x CD3 Bispecific Antibody) Who Receive a Kidney Transplant

Quick Facts

Study Start:2023-10-19
Study Completion:2027-12-24
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05106387

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 70 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. 1. Received at least 1 dose of treatment with vonsetamig in study R5459-RT-1944 \[NCT05092347\].
  2. 2. Received after acceptable crossmatching, a kidney transplant while enrolled in study R5459-RT-1944
  3. 3. Willing and able to comply with clinic visits and study-related procedures
  4. 4. Provide informed consent signed by study patient or legally acceptable representative
  1. 1.There are no exclusion criteria for this study.

Contacts and Locations

Study Contact

Clinical Trials Administrator
CONTACT
844-734-6643
clinicaltrials@regeneron.com

Principal Investigator

Clinical Trial Management
STUDY_DIRECTOR
Regeneron Pharmaceuticals

Study Locations (Sites)

Cedars-Sinai Medical Center
Los Angeles, California, 90048
United States
University of California Irvine
Orange, California, 92868
United States
Connie Frank Transplant Center at UCSF
San Francisco, California, 94143
United States
Yale University of Medicine
New Haven, Connecticut, 06520
United States
Comprehensive Transplant Center
Chicago, Illinois, 60611
United States
John Hopkins Hospital
Baltimore, Maryland, 21224
United States
New York University Langone Health
New York, New York, 10016
United States
Penn Transplant Institute
Philadelphia, Pennsylvania, 19104
United States

Collaborators and Investigators

Sponsor: Regeneron Pharmaceuticals

  • Clinical Trial Management, STUDY_DIRECTOR, Regeneron Pharmaceuticals

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-10-19
Study Completion Date2027-12-24

Study Record Updates

Study Start Date2023-10-19
Study Completion Date2027-12-24

Terms related to this study

Keywords Provided by Researchers

  • Kidney Transplant

Additional Relevant MeSH Terms

  • Chronic Kidney Disease (CKD)